0001144204-17-064741.txt : 20180124 0001144204-17-064741.hdr.sgml : 20180124 20171221143834 ACCESSION NUMBER: 0001144204-17-064741 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20171221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASI Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0000895051 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581959440 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-864-2600 MAIL ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ENTREMED INC DATE OF NAME CHANGE: 19960415 CORRESP 1 filename1.htm

	December 21, 2017

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:

Christine Westbrook

CASI Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No. 333-222046

Request for Acceleration

Ladies and Gentlemen:

CASI Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission accelerate the effective date of the above referenced registration statement so that it may become effective at 4:00 p.m. on December 22, 2017 or as soon thereafter as practicable.

Please call Richard E. Baltz at (202) 942-5124 with any questions about this request.

	Sincerely,


	/s/ Cynthia W. Hu
	Cynthia W. Hu
	Chief Operating Officer, General Counsel & Secretary